Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
For adults, a maximum dose of 266 mg (20 mL) is recommended, based on:
For pediatric patients aged 6 to less than 17 years, dosing is weight based: 4 mg/kg (up to a maximum of 266 mg)
1 out of 3 Americans avoids the dentist due to dental fear1*
70% of patients are prescribed opioids for postsurgical pain after a third molar extraction2
33% increased risk of future opioid use in patients prescribed opioids legitimately in 12th grade3
Non-opioid EXPAREL is a proven, long-lasting anesthetic that controls pain for the first few days after surgery—when your patients need relief most. In third molar extraction, dental implants, and orthognathic and craniofacial procedures, opioid-sparing EXPAREL consistently demonstrates4-7:
59% REDUCTION in total prescribed opioids in MMEs4; 47.1 vs 113.8 MMEs; rate ratio, 0.41 (0.39–0.44) (P<0.0001)
57% REDUCTION in opioid prescription refill rate; 3.3% vs 7.7%, (P=0.028)
97% REDUCTION in pain scores in the first 4 hours of the postsurgical period 0.1 ± 0.5 (SD) vs 3.7 ± 3.5 (SD) (P<0.001)
SIGNIFICANT REDUCTION in pain scores in the first 24 hours of the postsurgical period; 12 (P=0.010), 16 (P=0.002), 20 (P=0.006), and 24 (P=0.009) hours
*According to a 2018 global survey by DentaVox
†The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
‡Results from a retrospective cross-sectional analysis of patients undergoing third molar extraction (N=600) receiving local infiltration with EXPAREL (n=300) compared with patients who did not receive EXPAREL (n=300).4
§Results from a retrospective cohort study of patients undergoing alveolar bone grafting with an open iliac crest bone harvest (N=38) receiving EXPAREL at the hip donor site (n=17) compared with patients receiving bupivacaine HCl at the hip donor site (n=21).5
Leading medical societies recommend opioid-minimizing pain management strategies to enhance recovery after oral and maxillofacial procedures
AAOMS
The oral and maxillofacial surgeon should avoid starting treatment with long-acting or extended-release opioid analgesics.8
AAOMS, American Association of Oral and Maxillofacial Surgeons (AAOMS).
See how your peers are using EXPAREL for optimal pain coverage
Spread awareness about your non-opioid approach for managing postsurgical pain with patients and the community
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.